Hafiz Muhammad Husnain Azam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hafiz Muhammad Husnain Azam has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Nazim Hussain
11 shared publicationsMehvish Mumtaz
9 shared publicationsZulqarnain Baqar
Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong, China
3 shared publications- Caglar Berkel
Department of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, Tokat, Turkey
2 shared publications Hadia Sarfraz
Department of Molecular Biology, University of Okara, Renala Khurd, Pakistan
2 shared publicationsHamna Tariq
Department of Molecular Biology, University of Okara, Renala Khurd, Pakistan
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Environmental Microbiology
- Vol. 28 (11) , e70468
Functional Genomics of a Zinc‐Solubilising Kosakonia cowanii RL ‐16 and Its Application for Zinc Biofortification in Oryza sativa L.
Zinc (Zn) is assumed to be the most important micronutrient due to its involvement in different biochemical processes. The daily requirement of Zn for the human body, however, cannot be fulfilled by traditional staple crops such as rice due to its low availability to plants, especially in alkaline soils. The present study was carried out to investigate the potential of indigenous microbial flora, isolated from different agroecological zones, for Zn solubilization and combating Zn deficiency in rice. Out of a total of 135 isolates, RL‐16, identified as Kosakonia cowanii , emerged as the most valuable resource for sustainable agricultural applications due to its incredible Zn solubilization potential and additional PGP characteristics. Gene mining of RL‐16 revealed the footprints of solubilization of Zn and other nutrients. Under microcosmic conditions, zinc content was significantly improved for the treatment with RL‐16 (134.7 mg/kg ± 0.6), compared to the control containing only an insoluble zinc source (107.7 mg/kg ± 1.6). Zinc translocation in seed (ZnSd) was enhanced by the application of RL‐16 across both varieties, which was also confirmed by field evaluation. This study demonstrates the whole genome sequence analysis of Kosakonia cowanii and its potential role in Zn biofortification for more targeted and sustainable agricultural practices.
- 2 November 2026
- Published by Wiley in Environmental Microbiology
- Vol. 28 (11) , e70468
Open AccessFunctional Genomics of a Zinc‐Solubilising Kosakonia cowanii RL ‐16 and Its Application for Zinc Biofortification in Oryza sativa L.
Zinc (Zn) is assumed to be the most important micronutrient due to its involvement in different biochemical processes. The daily requirement of Zn for the human body, however, cannot be fulfilled by traditional staple crops such as rice due to its low availability to plants, especially in alkaline soils. The present study was carried out to investigate the potential of indigenous microbial flora, isolated from different agroecological zones, for Zn solubilization and combating Zn deficiency in rice. Out of a total of 135 isolates, RL‐16, identified as Kosakonia cowanii , emerged as the most valuable resource for sustainable agricultural applications due to its incredible Zn solubilization potential and additional PGP characteristics. Gene mining of RL‐16 revealed the footprints of solubilization of Zn and other nutrients. Under microcosmic conditions, zinc content was significantly improved for the treatment with RL‐16 (134.7 mg/kg ± 0.6), compared to the control containing only an insoluble zinc source (107.7 mg/kg ± 1.6). Zinc translocation in seed (ZnSd) was enhanced by the application of RL‐16 across both varieties, which was also confirmed by field evaluation. This study demonstrates the whole genome sequence analysis of Kosakonia cowanii and its potential role in Zn biofortification for more targeted and sustainable agricultural practices.
- 1 September 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 593
Electrochemical immunosensors for KIM-1 and NGAL: recent advances toward early and point-of-care diagnosis of acute kidney injury
- 1 September 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 593
Electrochemical immunosensors for KIM-1 and NGAL: recent advances toward early and point-of-care diagnosis of acute kidney injury
- 24 July 2026
- Published by Elsevier
- p. 75-130
Ultrasound-responsive nanocarriers for biomedical application
- 24 July 2026
- Published by Elsevier
- p. 75-130
Ultrasound-responsive nanocarriers for biomedical application
- 6 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6277-6319
MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies—advances and challenges
Neurodegenerative diseases (NDDs) pose significant challenges in early detection and treatment due to their complex pathophysiology and heterogeneous clinical presentations. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, have emerged as promising diagnostic biomarkers and therapeutic targets in NDDs. Pathological examination of affected tissues reveals early synaptic dysfunction, protein misfolding, and neuroinflammation occur prior to overt clinical symptoms, highlighting the importance of sensitive diagnostics approaches in prodromal stages. This review summarizes for researchers on the role of miRNAs in NDDs by examining their diagnostic potential in biofluids such as blood and cerebrospinal fluid, and their therapeutic applicability through inhibition or replacement strategies. Literature from peer-reviewed databases was assessed with a focus on recent advances in molecular detection platforms, computational modeling of miRNA–mRNA interactions, and preclinical/clinical investigations. More than 2600 human miRNAs have been identified, collectively regulating over half of mammalian protein-coding genes. Quantitative methodologies, particularly reverse transcription quantitative PCR (RT-qPCR), enable reliable miRNA profiling, facilitating early diagnosis and prognosis of NDDs. Therapeutic strategies, including antagomirs, mimics, sponges and viral or non-viral delivery systems, show promise in modulating disease pathways. However, significant challenges remain, including variability in miRNA extraction and quantification protocols, off-target effects, delivery barriers across the blood brain barrier and limited reproducibility across studies. MiRNAs represent a class of molecular tools with potential to transform diagnostics and therapeutics in NDDs. Future research should prioritize methodological standardization, validation in large multicenter cohorts, and improved computational approaches to elucidate miRNA-mediated regulatory networks in NDDs. Replication studies and translational research are essential harnessing the the full clinical utility of miRNAs in the management of Alzheimer disease, Parkinson disease and other NDDs. Graphical Abstract
- 6 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6277-6319
MicroRNAs in neurodegenerative diseases: from molecular mechanisms to clinical biomarkers, detection methods and therapeutic strategies—advances and challenges
Neurodegenerative diseases (NDDs) pose significant challenges in early detection and treatment due to their complex pathophysiology and heterogeneous clinical presentations. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, have emerged as promising diagnostic biomarkers and therapeutic targets in NDDs. Pathological examination of affected tissues reveals early synaptic dysfunction, protein misfolding, and neuroinflammation occur prior to overt clinical symptoms, highlighting the importance of sensitive diagnostics approaches in prodromal stages. This review summarizes for researchers on the role of miRNAs in NDDs by examining their diagnostic potential in biofluids such as blood and cerebrospinal fluid, and their therapeutic applicability through inhibition or replacement strategies. Literature from peer-reviewed databases was assessed with a focus on recent advances in molecular detection platforms, computational modeling of miRNA–mRNA interactions, and preclinical/clinical investigations. More than 2600 human miRNAs have been identified, collectively regulating over half of mammalian protein-coding genes. Quantitative methodologies, particularly reverse transcription quantitative PCR (RT-qPCR), enable reliable miRNA profiling, facilitating early diagnosis and prognosis of NDDs. Therapeutic strategies, including antagomirs, mimics, sponges and viral or non-viral delivery systems, show promise in modulating disease pathways. However, significant challenges remain, including variability in miRNA extraction and quantification protocols, off-target effects, delivery barriers across the blood brain barrier and limited reproducibility across studies. MiRNAs represent a class of molecular tools with potential to transform diagnostics and therapeutics in NDDs. Future research should prioritize methodological standardization, validation in large multicenter cohorts, and improved computational approaches to elucidate miRNA-mediated regulatory networks in NDDs. Replication studies and translational research are essential harnessing the the full clinical utility of miRNAs in the management of Alzheimer disease, Parkinson disease and other NDDs. Graphical Abstract
- Open Access
- 1 June 2025
- Published by 101RESEARCH (Pvt.) Ltd. in Indus Journal of Bioscience Research
- Vol. 3 (6) , 151-160
Computational Approaches to Design Cytotoxic Lymphocyte (CTL) Epitope-Based Vaccine Targeting the Spike (S) Protein of SARS-CoV-2
The ongoing global threat posed by SARS-CoV-2 necessitates the rapid development of effective vaccines. This study employed a computational pipeline to design a multi-epitope vaccine targeting the spike (S) glycoprotein of SARS-CoV-2. Cytotoxic T lymphocyte (CTL) epitopes were predicted using immunoinformatics tools and were screened based on their non-toxicity, immunogenicity, and antigenicity. High-affinity epitopes were sequentially linked via AAY linkers to construct a rationally designed vaccine candidate. The tertiary structure of the construct was modeled and evaluated for structural stability and desirable physicochemical properties. To assess immunogenic potential, molecular docking was performed with key immune receptors, including Toll-like receptor 3 (TLR3) and major histocompatibility complex class I (MHC-I), demonstrating strong and specific binding interactions. Furthermore, the vaccine gene was codon-optimized and in silico cloned into the pET-28b(+) expression vector, yielding a construct of 5476 base pairs. The collective in silico findings support the designed multi-epitope vaccine as a promising candidate capable of inducing robust and long-lasting cell-mediated immunity against SARS-CoV-2. Experimental validation is warranted to confirm these computational predictions.
- 1 June 2025
- Published by 101RESEARCH (Pvt.) Ltd. in Indus Journal of Bioscience Research
- Vol. 3 (6) , 151-160
Open AccessComputational Approaches to Design Cytotoxic Lymphocyte (CTL) Epitope-Based Vaccine Targeting the Spike (S) Protein of SARS-CoV-2
The ongoing global threat posed by SARS-CoV-2 necessitates the rapid development of effective vaccines. This study employed a computational pipeline to design a multi-epitope vaccine targeting the spike (S) glycoprotein of SARS-CoV-2. Cytotoxic T lymphocyte (CTL) epitopes were predicted using immunoinformatics tools and were screened based on their non-toxicity, immunogenicity, and antigenicity. High-affinity epitopes were sequentially linked via AAY linkers to construct a rationally designed vaccine candidate. The tertiary structure of the construct was modeled and evaluated for structural stability and desirable physicochemical properties. To assess immunogenic potential, molecular docking was performed with key immune receptors, including Toll-like receptor 3 (TLR3) and major histocompatibility complex class I (MHC-I), demonstrating strong and specific binding interactions. Furthermore, the vaccine gene was codon-optimized and in silico cloned into the pET-28b(+) expression vector, yielding a construct of 5476 base pairs. The collective in silico findings support the designed multi-epitope vaccine as a promising candidate capable of inducing robust and long-lasting cell-mediated immunity against SARS-CoV-2. Experimental validation is warranted to confirm these computational predictions.
- 9 March 2025
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 340, 103473
Fusion of enzymatic proteins: Enhancing biological activities and facilitating biological modifications
- 9 March 2025
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 340, 103473
Fusion of enzymatic proteins: Enhancing biological activities and facilitating biological modifications
- Open Access
- 19 January 2025
- Published by UNS Solo in Asian Journal of Natural Product Biochemistry
- Vol. 23 (1)
Harnessing L-asparaginase from Solanaceae plants: Purification and molecular dynamics studies for cancer targeting
Aisha A, Sajjad A, Munawar N, Azam HMH, Ishtiaq U, Nawaz S. 2025. Harnessing L-asparaginase from Solanaceae plants: Purification and molecular dynamics studies for cancer targeting. Asian J Nat Prod Biochem 23: 27-37. Conventional chemotherapeutic regimens have their adverse effects. Our research, however, offers a potential breakthrough in cancer treatment. We have discovered that l-asparaginase from plant sources can selectively target L-asparagine, the nutritional requirement of cancer cells. The aim was to elucidate the function and mechanism of action of anticancer and bactericidal plant-sourced L-asparaginase protein via proteomics. Biochemical, chromatographic techniques and SDS PAGE were employed for purifying L-asparaginase from Solanaceae plants, including Datura innoxia, Atropa belladonna, Hyoscyamus niger (leaves), Lycopersicum esculentum (fruit), Solanum tuberosum (roots), and Ipomoea batatas (roots). Michaelis-Menten and Lineweaver Burk's plot demonstrated the characterization of the extracted protein from D. innoxia, which exhibited the maximum enzyme activity. Further, molecular dynamics simulations were employed to establish antimicrobial efficiency (through potato disc assays) and to determine the antitumor efficiency. Kinetic studies of L-asparaginase from D. innoxia revealed optimal activity at pH 8-8.5 and 37°C with [S]=8 ?g/mL, Km 0.1766 ?mol provided 1/2V max 0.525 ?mol/min, while the protein band of approximately 30 kDa. Ethanolic extracts inhibited growth 54.5, 33.30, and 45.65% among Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, respectively, with MIC 6.25 mg/dL. L-asparaginase anticancer mediation was validated using molecular dynamics simulations (InterPro Scan), identifying novel domain IPR027474 and active sites IPR020827 and IPR027475. This mechanism provided insights into anticancer action and potential sources for combinational therapies in clinical oncology.
- 19 January 2025
- Published by UNS Solo in Asian Journal of Natural Product Biochemistry
- Vol. 23 (1)
Open AccessHarnessing L-asparaginase from Solanaceae plants: Purification and molecular dynamics studies for cancer targeting
Aisha A, Sajjad A, Munawar N, Azam HMH, Ishtiaq U, Nawaz S. 2025. Harnessing L-asparaginase from Solanaceae plants: Purification and molecular dynamics studies for cancer targeting. Asian J Nat Prod Biochem 23: 27-37. Conventional chemotherapeutic regimens have their adverse effects. Our research, however, offers a potential breakthrough in cancer treatment. We have discovered that l-asparaginase from plant sources can selectively target L-asparagine, the nutritional requirement of cancer cells. The aim was to elucidate the function and mechanism of action of anticancer and bactericidal plant-sourced L-asparaginase protein via proteomics. Biochemical, chromatographic techniques and SDS PAGE were employed for purifying L-asparaginase from Solanaceae plants, including Datura innoxia, Atropa belladonna, Hyoscyamus niger (leaves), Lycopersicum esculentum (fruit), Solanum tuberosum (roots), and Ipomoea batatas (roots). Michaelis-Menten and Lineweaver Burk's plot demonstrated the characterization of the extracted protein from D. innoxia, which exhibited the maximum enzyme activity. Further, molecular dynamics simulations were employed to establish antimicrobial efficiency (through potato disc assays) and to determine the antitumor efficiency. Kinetic studies of L-asparaginase from D. innoxia revealed optimal activity at pH 8-8.5 and 37°C with [S]=8 ?g/mL, Km 0.1766 ?mol provided 1/2V max 0.525 ?mol/min, while the protein band of approximately 30 kDa. Ethanolic extracts inhibited growth 54.5, 33.30, and 45.65% among Escherichia coli, Staphylococcus aureus, and Bacillus subtilis, respectively, with MIC 6.25 mg/dL. L-asparaginase anticancer mediation was validated using molecular dynamics simulations (InterPro Scan), identifying novel domain IPR027474 and active sites IPR020827 and IPR027475. This mechanism provided insights into anticancer action and potential sources for combinational therapies in clinical oncology.
- Open Access
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1386735
MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review
Neurodegenerative diseases (NDs) are characterized by abnormalities within neurons of the brain or spinal cord that gradually lose function, eventually leading to cell death. Upon examination of affected tissue, pathological changes reveal a loss of synapses, misfolded proteins, and activation of immune cells—all indicative of disease progression—before severe clinical symptoms become apparent. Early detection of NDs is crucial for potentially administering targeted medications that may delay disease advancement. Given their complex pathophysiological features and diverse clinical symptoms, there is a pressing need for sensitive and effective diagnostic methods for NDs. Biomarkers such as microRNAs (miRNAs) have been identified as potential tools for detecting these diseases. We explore the pivotal role of miRNAs in the context of NDs, focusing on Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, and Amyotrophic Lateral Sclerosis. The review delves into the intricate relationship between aging and NDs, highlighting structural and functional alterations in the aging brain and their implications for disease development. It elucidates how miRNAs and RNA-binding proteins are implicated in the pathogenesis of NDs and underscores the importance of investigating their expression and function in aging. Significantly, miRNAs exert substantial influence on post-translational modifications (PTMs), impacting not just the nervous system but a wide array of tissues and cell types as well. Specific miRNAs have been found to target proteins involved in ubiquitination or de-ubiquitination processes, which play a significant role in regulating protein function and stability. We discuss the link between miRNA, PTM, and NDs. Additionally, the review discusses the significance of miRNAs as biomarkers for early disease detection, offering insights into diagnostic strategies.
- 31 May 2024
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 17, 1386735
Open AccessMicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review
Neurodegenerative diseases (NDs) are characterized by abnormalities within neurons of the brain or spinal cord that gradually lose function, eventually leading to cell death. Upon examination of affected tissue, pathological changes reveal a loss of synapses, misfolded proteins, and activation of immune cells—all indicative of disease progression—before severe clinical symptoms become apparent. Early detection of NDs is crucial for potentially administering targeted medications that may delay disease advancement. Given their complex pathophysiological features and diverse clinical symptoms, there is a pressing need for sensitive and effective diagnostic methods for NDs. Biomarkers such as microRNAs (miRNAs) have been identified as potential tools for detecting these diseases. We explore the pivotal role of miRNAs in the context of NDs, focusing on Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Huntington’s disease, and Amyotrophic Lateral Sclerosis. The review delves into the intricate relationship between aging and NDs, highlighting structural and functional alterations in the aging brain and their implications for disease development. It elucidates how miRNAs and RNA-binding proteins are implicated in the pathogenesis of NDs and underscores the importance of investigating their expression and function in aging. Significantly, miRNAs exert substantial influence on post-translational modifications (PTMs), impacting not just the nervous system but a wide array of tissues and cell types as well. Specific miRNAs have been found to target proteins involved in ubiquitination or de-ubiquitination processes, which play a significant role in regulating protein function and stability. We discuss the link between miRNA, PTM, and NDs. Additionally, the review discusses the significance of miRNAs as biomarkers for early disease detection, offering insights into diagnostic strategies.
- Open Access
- 31 March 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 100-106
SARS-CoV-2 and Angiotensin-Converting Enzyme-2 Receptor Interaction Blocker– an In-Silico Approach
The global COVID-19 pandemic, instigated by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has led to substantial morbidity and mortality on a worldwide scale. While COVID-19 vaccines offer hope, the emergence of mutated viral strains necessitates the development of FDA-approved drugs to address future outbreaks. Objective: To examine prospective antiviral medications through an analysis of the interaction between the spike protein of SARS-CoV-2 and Angiotensin-converting enzyme-2 (ACE-2) receptors, which play a pivotal role in facilitating viral entry into host cells. Methods: Molecular docking was employed to assess the binding affinities of various protease inhibitors with ACE-2 receptors. Natural proteases, including Furin and Transmembrane serine protease 2 (TMPRSS2), cleave viral spike proteins into S1 and S2 subunits, facilitating fusion with ACE-2 receptors. We assessed the binding energies of Indinavir, Nafamostat, Fosamprenavir, Lopinavir, and Boceprevir to inhibit this interaction with a sense of optimism for their potential therapeutic applications. Results: Our findings suggest potential treatments for COVID-19, with Indinavir, Nafamostat, Fosamprenavir, Lopinavir, and Boceprevir displaying promising binding energies of -9.6 kcal/mol, -8.4 kcal/mol, -7.7 kcal/mol, and -7.5 kcal/mol, respectively. Conclusions: While promising, further clinical trials are important to potentially evaluate the efficacy and safety of these proposed drugs in combating COVID-19 and its variants.
- 31 March 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 100-106
Open AccessSARS-CoV-2 and Angiotensin-Converting Enzyme-2 Receptor Interaction Blocker– an In-Silico Approach
The global COVID-19 pandemic, instigated by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has led to substantial morbidity and mortality on a worldwide scale. While COVID-19 vaccines offer hope, the emergence of mutated viral strains necessitates the development of FDA-approved drugs to address future outbreaks. Objective: To examine prospective antiviral medications through an analysis of the interaction between the spike protein of SARS-CoV-2 and Angiotensin-converting enzyme-2 (ACE-2) receptors, which play a pivotal role in facilitating viral entry into host cells. Methods: Molecular docking was employed to assess the binding affinities of various protease inhibitors with ACE-2 receptors. Natural proteases, including Furin and Transmembrane serine protease 2 (TMPRSS2), cleave viral spike proteins into S1 and S2 subunits, facilitating fusion with ACE-2 receptors. We assessed the binding energies of Indinavir, Nafamostat, Fosamprenavir, Lopinavir, and Boceprevir to inhibit this interaction with a sense of optimism for their potential therapeutic applications. Results: Our findings suggest potential treatments for COVID-19, with Indinavir, Nafamostat, Fosamprenavir, Lopinavir, and Boceprevir displaying promising binding energies of -9.6 kcal/mol, -8.4 kcal/mol, -7.7 kcal/mol, and -7.5 kcal/mol, respectively. Conclusions: While promising, further clinical trials are important to potentially evaluate the efficacy and safety of these proposed drugs in combating COVID-19 and its variants.